

Cytokinetics, Incorporated  
Condensed Statement of Operations  
(in thousands, except share and per share data)  
(unaudited)

	Three Months Ended	
	March 31, 2010	March 31, 2009
Revenues:		
Research and development	\$ 621	\$ 20
License revenues	-	3,058
Total revenues	621	3,078
Operating expenses:		
Research and development	9,068	9,959
General and administrative	3,836	4,020
Restructuring charges	-	(58)
Total operating expenses	12,904	13,921
Operating loss	(12,283)	(10,843)
Interest and other, net	94	158
Net loss	<u>\$ (12,189)</u>	<u>\$ (10,685)</u>
Net loss per common share - basic and diluted	\$ (0.20)	\$ (0.21)
Weighted average shares used in computing net loss per common share - basic and diluted	61,995,376	51,581,921

- more -

Cytokinetics, Incorporated  
Condensed Balance Sheet  
(in thousands)  
(unaudited)

	March 31, 2010	December 31, 2009
<b>Assets</b>		
Cash and cash equivalents	\$ 20,715	\$ 25,561
Short-term investments	67,091	71,266
Investment in auction rate securities	15,311	15,542
Investment put option	2,339	2,358
Related party receivables	20	189
Other current assets	1,613	2,005
Total current assets	107,089	116,921
Property and equipment, net	3,282	3,713
Restricted investments	1,233	1,674
Other assets	289	291
<b>Total assets</b>	\$ 111,893	\$ 122,599
 <b>Liabilities and stockholders' equity</b>		
Current liabilities	\$ 17,534	\$ 20,186
Long-term obligations	724	985
Stockholders' equity	93,635	101,428
<b>Total liabilities and stockholders' equity</b>	\$ 111,893	\$ 122,599

Cytokinetics, Incorporated  
 Reconciliation of GAAP amounts to non-GAAP amounts  
 (Unaudited)  
 (In thousands)

	Three Months Ended March 31,	
	2010	2009
GAAP net loss	\$ (12,189)	\$ (10,685)
Non-cash deferred revenue related to Amgen collaboration	-	(3,074)
Non-cash stock-based compensation	994	1,249
Non-cash depreciation, amortization, and other	489	447
Non-GAAP net loss	\$ (10,706)	\$ (12,063)